Katalin Susztak
Nephrology · Philadelphia, PANPI 1124118096
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $161,572 of the $192,345 with a category attached, or 84.0%. 17 manufacturers reported payments, led by Pfizer at 59.5% of the total. 2025 is the largest year on record at $50,553, 2.8 times the $18,281 reported in 2019. Among nephrology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 66 payments — averaging $2914.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$114K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$36K
- Nippon Boehringer Ingelheim Co., Ltd.$14K
- Vertex$7K
- Astrazeneca UK Limited$4K
- Janssen Research & Development, LLC$3K
- plus $14K from 11 others
Across 20 payments — averaging $231,294 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kyowa Kirin Co., Ltd$1.4M
- Novo Nordisk AS$725K
- Genentech, Inc.$720K
- GSK$655K
- Boehringer Ingelheim$596K
- Astrazeneca AB$410K
- plus $130K from 2 others
What the payments were for
- Consulting fees$161,57284%
- Speaking & faculty fees$7,0004%
- Travel & lodging$21,07511%
- Food & beverage$2,6981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 31 | $114,464 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 14 | $35,920 |
| Nippon Boehringer Ingelheim Co., Ltd. | 2 | $14,383 |
| Vertex | 2 | $6,866 |
| Astrazeneca UK Limited | 2 | $3,833 |
| Janssen Research & Development, LLC | 1 | $3,150 |
| Radius Health, Inc. | 1 | $2,940 |
| Astellas Pharma Inc | 1 | $2,435 |
| GSK | 1 | $2,300 |
| Novo Nordisk AS | 3 | $2,200 |
| Bayer | 1 | $1,800 |
| Genentech USA, Inc. | 2 | $1,681 |
| Genentech, Inc. | 1 | $147 |
| Sanofi-aventis U.S. LLC | 1 | $76 |
| Regeneron | 1 | $71 |
| Vifor Pharma, Inc. | 1 | $66 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$14,358
- Non-Covered$1,800
How this compares
$192,345 in reported general payments places this provider in the 95th percentile of 586 nephrology providers in Pennsylvania.
Other nephrology in Philadelphia
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Ellie KelepourisPhiladelphia$287K
- Abdallahsassine GearaPhiladelphia$225K
- Debbie Cohen SteinPhiladelphia$112K
- Laura DemberPhiladelphia$110K
- Jonathan HoganPhiladelphia$100K
- Michael YoslovPhiladelphia$79K
- Michael LevinPhiladelphia$55K
- Gaia MuallemPhiladelphia$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.